[Dyskinetic syndrome in children following Thalamonal premedication]

Area of Science:

• Pediatric Neurology
• Pharmacology

Background:

• Thalamonal, a combination antipsychotic medication, is sometimes used for premedication in pediatric patients.
• Adverse neurological effects of medications in children require careful monitoring and management.

Observation:

• Two pediatric cases presented with a dyskinetic syndrome following Thalamonal administration.
• The observed syndrome involved involuntary, abnormal movements characteristic of dyskinesia.

Findings:

• The dyskinetic syndrome appeared to be a direct consequence of Thalamonal premedication.
• Biperiden (Akineton) was identified as a suitable therapeutic agent for managing this specific adverse event.

Implications:

• This report highlights a potential risk associated with Thalamonal in pediatric populations.
• Clinical guidelines should be updated to recommend biperiden and contraindicate physostigmine for Thalamonal-induced dyskinesia in children.